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Abstract 1 
Objective: Aronia melanocarpa is a rich source of polyphenolic compounds. Most 2 
studies investigating the cardiovascular health benefits of berries have been 3 
conducted in individuals at high risk or with cardiovascular disease using relatively 4 
high amounts of fruit or juice that are impractical for daily consumption. This study 5 
aims to investigate the effect of dietary achievable amounts of aronia berries on 6 
vascular function and their impact on the faecal microbiota composition in a young and 7 
healthy population.  8 
Methods: A double-blind, placebo-controlled, parallel designed study was conducted 9 
in 66 healthy male adults randomly allocated to a polyphenol rich extract (40% total 10 
(poly)phenols, equivalent to 75 g of aronia berries), a whole fruit powder (4% total 11 
(poly)phenols, equivalent to 10 g of aronia berries) or placebo (artificially coloured 12 
maltodextrin, 0% total (poly)phenols). Each participant ingested one 500 mg capsule 13 
every day for 12 weeks. Flow-mediated dilation (FMD), pulse wave velocity, 14 
augmentation index, blood pressure, heart rate and serum biochemistry were 15 
assessed at baseline and after 12 weeks. FMD was also measured 2 h after capsule 16 
intake on both visits. Plasma (poly)phenol metabolites were analysed using micro-17 
elution solid phase-extraction coupled with LC-MS. Gut microbiota composition was 18 
determined via 16S rRNA Sequencing in stool samples collected at baseline and at 19 
12 weeks. 20 
Results: Consumption of aronia whole fruit and aronia extract powder for 12 weeks 21 
led to a significant increase in FMD over control of 0.9 ± 0.4 % (95 % CI: 0.13 to 1.72) 22 
and 1.2 ± 0.4 % (95 % CI: 0.36 to 1.97) respectively. Acute improvements in FMD 23 
were also observed 2h after consumption of aronia extract on day 1 (1.1 ± 0.3, 24 
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p=0.003) and 12 weeks later (1.5 ± 0.4 %, p=0.0001). A parallel increase in circulating 25 
plasma phenolic metabolites was found 2 h post-consumption and after 12 week daily 26 
consumption of the aronia treatments even after an overnight fast. No significant 27 
differences in arterial stiffness, blood pressure or blood lipids were found. A 28 
correlations analysis identified potential associations between aronia-derived phenolic 29 
metabolites and specific gut microbial genera.   30 
Conclusions: In healthy young men, acute and daily consumption of aronia berry 31 
(poly)phenols improved endothelial function and modulated gut microbiota 32 
composition indicating that regular aronia consumption has the potential to maintain 33 
cardiovascular health in healthy individuals at low risk of cardiovascular disease.  34 
Funding: The authors acknowledge Naturex-DBS for providing the capsules and for 35 
funding the study.  36 
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1. Introduction  37 
Diet is one of the most important lifestyle factors greatly influencing the incidence and 38 
progression of cardiovascular diseases (CVD) (1). Convincing evidence from 39 
epidemiological studies suggests that high intakes of fruit and vegetables reduces the 40 
risk of developing coronary heart disease and stroke (2-4). This may be, in part, thanks 41 
to the high amounts of bioactive compounds present in fruits and vegetables (5). More 42 
evidence from human intervention studies suggest that daily consumption of foods 43 
high in (poly)phenols, such as tea, cocoa and berries, may improve long term vascular 44 
health (6). A limited number of randomized controlled trials (RCTs) have demonstrated 45 
small improvements in blood lipids, blood pressure and endothelial function following 46 
daily consumption of berries or other anthocyanin rich foods (7-9). However, due to 47 
the low number of RCTs and large heterogeneity between study designs, study 48 
populations and interventions used, there are some inconsistencies in findings, as 49 
decribed by one meta-analysis on anthocyanin-rich foods (10).  50 
The gut microbiome has an important influence on human health and a limited amount 51 
of evidence indicates that gut microbes might be modulated upon consumption of 52 
dietary (poly)phenols by humans. In a study by Queipo-Ortuño et al., intake of red wine 53 
by healthy volunteers over 4 weeks was parralelled with a significant increase of 54 
several microbial communities including Bifidobacterium, Bacteroides and 55 
Enterococcus (11). Even more specifically, anthocyanin microbial metabolites from 56 
red wine were previously associated with higher levels of Bifidobacterium, which has 57 
been associated with beneficial health effects (12, 13). Similarly, in a study with 58 
healthy humans, significant increases in Bifidobacterium was observed 6-weeks after 59 
consumption of an anthocyanin-rich wild blueberry powder (14).  60 
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One berry of growing interest is Aronia melanocarpa, as it has one of the highest 61 
(poly)phenol content compared with other fruits (15, 16).  Few RCT’s have shown that 62 
daily aronia berry consumption decreased blood pressure in individuals with 63 
cardiovascular disease (17), metabolic syndrome (18) or at high risk of CVD (17, 19). 64 
Whether or not regular aronia consumption has the potential to maintain and/or 65 
improve cardiovascular health in individuals without CVD and those with low degrees 66 
of cardiovascular risk, that is, healthy subjects, has not been evaluated. In addition, 67 
the effects of aronia berries on FMD have not been investigated before in a RCT. The 68 
primary aim of the present study was to investigate the effects of acute and daily 69 
consumption of dietary achievable amounts of aronia whole berries and a 70 
(poly)phenol-rich extract on endothelial function in a population of young individuals at 71 
low risk of CVD. Finally, to explore the role of aronia intake on the gut microbial 72 
ecology, characterization and profiling of gut microbiota was assessed as a secondary 73 
outcome.  74 
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2. Methods 75 
2.1. Intervention Study Subjects 76 
Sixty-six healthy male volunteers aged 18-45 years were recruited from King’s College 77 
London and the surrounding area. Health was ascertained by a routine clinical physical 78 
examination and specific medical history questionnaire. Volunteers with manifest 79 
cardiovascular disease including coronary artery disease, cerebrovascular disease 80 
and peripheral artery disease were excluded (Figure 1). Additional exclusions were: 81 
hypertension (140 mmHg SBP and 90 mmHg DBP), body mass index 30kg/m2, 82 
diabetes mellitus and metabolic syndrome, acute inflammation, terminal renal failure, 83 
malignancies and abnormal heart rhythm (60 or 100 bpm). Subjects were also 84 
excluded if they had allergies to berries or other significant foods, were using 85 
medication or other dietary supplements, smoked an irregular number of cigarettes 86 
per day or were planning to quit in the next 6 months.  87 
 88 
2.2. Study Design  89 
A three-arm, double-blind, parallel, randomized controlled trial was conducted. 90 
Informed consent was obtained and subjects were randomized to the treatments. We 91 
investigated the effects of two formulations of aronia berry capsules on vascular 92 
function compared with a placebo control capsule. Measurements were taken at 93 
baseline and 2 h post-acute consumption, and this was repeated 12 weeks after daily 94 
capsule consumption.  95 
Once participants were screened and included, they attended two visits, at baseline 96 
and 12 weeks later. Participants were instructed not to alter their usual dietary habits 97 
nor their physical activity throughout the study. Participants were asked to refrain from 98 
eating high (poly)phenol products 24 h prior to the first visit, such as red wine and 99 
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beer, fruits and vegetables, nuts, olive oil, coffee, chocolate or cocoa products and 100 
tea. Dietary recalls (24 h) were completed at the start of each visit to monitor the low 101 
(poly)phenol diet. Food diaries and physical activity questionnaires were completed 102 
before and during the trial to ensure their habitual dietary and fluid intake remained 103 
consistent. Additionally, participants were fasted 12 h prior to each visit. 104 
Measurements of FMD, peripheral BP, PWV, AIx as well as blood samples were all 105 
taken at baseline (0 h) then again 2 h post-acute consumption of one capsule (Figure 106 
2). Stool samples were collected by the participants, using Omnigene-gut stool kits 107 
(DNA Genotek), and stored at -20C at the beginning of each visit. Participants were 108 
followed up three times throughout the 12-week period via phone to ensure no adverse 109 
events occurred.  110 
The study investigated both the acute (0-2 h) and chronic (0-12 weeks) effects of 111 
aronia berry (poly)phenols. The primary endpoint was endothelial function measured 112 
by flow-mediated dilation (FMD) using high-resolution ultrasound. Secondary 113 
endpoints included; pulse-wave velocity (PWV), augmentation index (AIx) and blood 114 
pressure (ambulatory and central) as determined automatically by a blood pressure 115 
monitoring system and applanation tonometry (Sphygmocor). Tertiary outcomes were 116 
plasma glucose, lipids, phenolic metabolites and gut microbiota.  117 
A team of qualified researchers enrolled participants on the study and assigned the 118 
interventions. Participants and researchers administering interventions and assessing 119 
outcomes were blinded to the intervention groups. An independent researcher 120 
generated the random allocation to treatment sequence using a random number 121 
generator with the purpose to allocate a specific number to every volunteer. This way, 122 
information about group allocation remained concealed. When study visits and 123 
analysis of primary outcome were completed, the independent researcher provided 124 
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the codes for unblinding and treatment grouping. The study was conducted in 125 
accordance to the guidelines stated in the current revision of the Declaration of 126 
Helsinki. All procedures were approved by King’s College London Ethics Committee 127 
(HR-15/16-3739; Registration number: NCT03041961). Volunteers were assessed 128 
and data were collected in detailed case report forms between February and July 2017 129 
in the Metabolic Research Unit at the Department of Nutritional Sciences of King’s 130 
College London.  131 
 132 
2.3. Aronia berry and control capsules  133 
Capsules were provided and manufactured by Naturex-DBS, LLC (Sagamore, 134 
Massachusetts, USA). The “aronia extract” capsules were concentrated extracts rich 135 
in (poly)phenols and processed by the removal of fibre and organic acids from 75 g 136 
aronia berries, containing 115 mg total (poly)phenols (Table 1). The “aronia whole 137 
fruit” capsules contained the equivalent to 10 g of the whole aronia berry fruit, and  138 
containing 20 mg of total (poly)phenols (Table 1). The control capsules, matched in 139 
appearance to both treatment capsules, contained maltodextrin and no (poly)phenols. 140 
The capsules were all matched in weight, carbohydrates and calories 141 
(Supplementary Table 1). Capsules were stored in plastic bottles with patient 142 
randomization number and unique treatment allocation number. 143 
 144 
2.4. Biochemical analyses  145 
Blood samples collected in EDTA/heparin tubes (Greiner Bio-One Ltd., 146 
Gloucestershire, UK) were centrifuged (1700 g; 15 min; 4˚C) immediately after 147 
collection. Plasma samples for (poly)phenol analysis were spiked with 2% formic acid 148 
and frozen at -80C. All clinical chemistry parameters including total cholesterol, LDL 149 
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and HDL-cholesterol, TAG (enzymatic photometric assay; RocheDiagnostics), 150 
glucose, HbA1c and whole blood count were analysed according to standard 151 
procedures (Biochemistry department, King’s College Hospital, Denmark Hill, 152 
London). 153 
 154 
2.5. Dietary assessment of background diet  155 
To assess dietary intake, 7-day food diaries by EPIC (European Prospective 156 
Investigation of Cancer; University of Cambridge) were completed by participants 157 
before the first visit (baseline) and at 11 weeks, before attending the second visit, to 158 
ensure habitual diets did not change during the study period. Participants were 159 
instructed to provide as much detail as possible about all food and drinks consumed. 160 
Average daily macro- and micronutrient composition of participant’s diet was analysed 161 
with the use of Nutritics (Nutritics Professional Diet Analysis, version 3.74; Nutritics 162 
Ltd). Polyphenol intakes were assessed using the online free database Phenol-163 
Explorer (http://phenol-explorer.eu). 164 
 165 
2.6. Vascular measurements  166 
FMD of the brachial artery was measured as previously described (4). Briefly, the 167 
diameter and flow velocity of the brachial artery was measured using a 12 MHz 168 
transducer (Vivid I, GE healthcare, Buckinghamshire, UK) and automatic edge-169 
detection software (Brachial Analyser, Medical imaging applications, Iowa City, USA) 170 
yielding standard deviations of mean differences between repeated measurements of 171 
less than 1%. Brachial artery diameter was measured 2 cm proximal to the elbow. 172 
Reactive hyperaemia was induced by 5 min of distal lower arm occlusion with 173 
sphygmomanometric cuff inflated to 180 mm Hg. Blood flow was recorded at baseline 174 
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using the Doppler mode. A forearm blood-pressure cuff was placed distal to the 175 
antecubital fossa and inflated to 180 mmHg for 5 min. Diameter was measured at 176 
baseline and immediately after cuff deflation at 20, 40, 60 and 80 sec, the diameter 177 
was assessed and FMD calculated as maximal relative diameter gain relative to 178 
baseline. The FMD was expressed as (diametermax-diameterbaseline)/diameterbaseline 179 
x100.   180 
Central BP parameters including AIx were measured by applanation tonometry using 181 
the SphygmoCor® (SMART medical, Gloucestershire, UK). Via a transfer function, the 182 
pressure waveform of the ascending aorta was synthesized. PWV was determined 183 
using measurements taken at the carotid and femoral artery as previously described 184 
(20).  185 
 186 
2.7. UHPLC Orbitrap MS analysis of plasma (poly)phenols 187 
Sample preparation and solid phase extraction for plasma (poly)phenol analysis was 188 
performed as described previously (21). The detection of plasma (poly)phenol 189 
metabolites was performed on a ExactiveTM Orbitrap Mass Spectrometer (Thermo 190 
Scientific, CA, USA) after separation on a Accela 1250 pump UHPLC system (Thermo 191 
Scientific, CA, USA). The autosampler injected of 5 µL of each sample in a Zorbax 192 
Eclipse Plus RRHD column 2.1 × 50 mm, 1.8 m with a compatible Eclipse Plus 193 
guardcolumn 2.1 × 5 mm, 1.8 m (Agilent, Waldbronn, Germany). The mobile phase 194 
consisted of 0.1% HCOOH (solvent A) and acetonitrile with 0.1% HCOOH (solvent B) 195 
in a 10 min gradient program. Quantification analysis of the plasma (poly)phenols was 196 
done using Xcalibur 2.2 (Thermo Scientific, CA, USA). 197 
 198 
2.8 Faecal sample collection and microbiome analysis 199 
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Faecal samples were collected in the week before each study visit using 200 
OMNIgene®•GUT self-collection tubes (DNA Genotek, Ottawa, Canada) and were 201 
stored in -20°C until further analysis. Microbiome analysis was performed by Clinical-202 
Microbiomics A/S (Copenhagen, Denmark) as described elsewhere (22). Briefly, Total 203 
microbial DNA was extracted from faeces using the 96-well NucleoSpin Soil DNA 204 
Isolation Kit  (Macherey-Nagel, Düren, Germany). PCR was performed with 16S rDNA 205 
primers S-D-Bact-0341-b-S-17 and reverse primer S-D-Bact-0785-a-A-21 with 206 
Illumina adapters attached (23) in order to target the V3-V4 regions. The following 207 
PCR program was used: 98 °C for 30 sec, 25x (98° C for 10 s, 55 °C for 20 s, 72 °C 208 
for 20 s), 72 °C for 5 min. Sequencing was performed on an Illumina MiSeq desktop 209 
sequencer using the MiSeq Reagent Kit V2 (Illumina, San Diego) for 2x250 bp paired- 210 
end sequencing.  211 
The 64-bit version of USEARCH (24) and mothur (25) were used in combination with 212 
several in-house programs for bioinformatics analysis of the sequence data. Following 213 
tag identification and trimming, all sequences from all samples were pooled. 214 
Sequences were clustered at 97 % sequence similarity. Additional suspected chimeric 215 
OTUs were discarded based on comparison with the Ribosomal Database Project 216 
classifier training set v9 (26) using UCHIME (27). Taxonomic assignment of OTUs was 217 
done using the method by Wang et al. (28) using the database from the Ribosomal 218 
Database Project. To find modifications in the microbiota structure associated with the 219 
aronia treatments, the samples were also longitudinally analysed by RandomForest. 220 
Briefly, Random Forest is a powerful classifier that identifies the best subset of 221 
features (here, relative genus abundance) that can discriminate between categories 222 
(time points). In particular, we applied the algorytm to the three groups separetely 223 
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(aronia extract, aronia whole fruit and control). The significance in the abundance of 224 
the relevant taxa were validated by Wilcoxon signed-rank tests. 225 
 226 
2.9. Power calculation and statistical analysis  227 
Power calculations were performed for the primary end point: change in FMD 228 
response after consumption. The power was based on the inter-individual variability 229 
for FMD measurement of the operator (SD = 1%). Assuming an 80% power, and a 230 
0.05 significance level, the total number subject required to provide sufficient power to 231 
detect a 1% difference change in FMD in a three-arm parallel study is 60 (n=20 per 232 
arm). Assuming a 10% drop out, 22 participants per arm should be recruited. Changes 233 
in FMD (%) between control and treatment groups were performed using a paired one-234 
way ANOVA with Tukey’s post-hoc test. Paired sample t-tests were performed on 235 
dietary assessment data to test for any significant differences. One-way ANOVA were 236 
performed on baseline dietary assessment data to ensure there were no differences 237 
in polyphenol, micro- or macronutrient intakes. Correlations are presented as 238 
Pearson’s r for non-normal distribution and as Spearman for normal distribution. 239 
Statistical analysis were performed with the use of IBM SPSS Statistics 22.0 240 
(Statistical Product and Service Solutions; IBM Corp) and GraphPad Prism version 7 241 
for Windows, (GraphPad Software, La Jolla California USA). Statistical significance is 242 
accepted at p<0.05.  243 
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3. Results  244 
3.1. Baseline characteristics of the study population  245 
A total of 84 volunteers were considered for participation in the study, of which 18 were 246 
excluded and 66 were included and randomised into the three intervention groups 247 
(Figure 1). The first study visit started in February and the last study visit ended in 248 
July 2017. A total of 3 follow-up calls were performed per participant between study 249 
visits. Two participants discontinued the study after the first visit, and 64 completed 250 
both visits (drop-out rate of 3%). The baseline characteristics of the different groups 251 
of healthy young men were all within the normal range and no differences were found 252 
between treatment groups (Table 2).  253 
3.2. Safety and tolerance of the interventions  254 
All the treatments were well tolerated and only 4 potential adverse events were 255 
reported over the course of the study, and were considered unrelated to the 256 
treatments: 2 of the participants in the aronia extract group reported unusual tiredness, 257 
1 volunteer in the aronia whole fruit group reported a persistent cough for a few weeks 258 
and in the control group, 1 volunteer reported food poisoning. Supplementary table 259 
2 shows the 10 safety parameters assessed, which remained in the normal healthy 260 
range after 12 weeks of treatment. 261 
3.4. Dietary assessment of food diaries and evaluation of background diet  262 
Analysis of the 7-day food diaries of study participants revealed no significant 263 
differences in micro- and macronutrient intakes as well as polyphenol intake between 264 
any treatment group prior to the start of the study (Supplementary Table 3). At 265 
baseline participants had an average daily (poly)phenol intake of 531 ± 357 mg, of 266 
which 23 ± 8 mg of that being anthocyanins (Supplementary Table 3).  267 
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3.3. Efficacy of aronia interventions on vascular function  268 
Our primary outcome was changes in FMD after 12 weeks daily supplementation. 269 
Repetitive intake of aronia extract and aronia whole fruit significantly improved FMD 270 
by 1.0 ± 0.2 % and 0.8 ± 0.3 % at baseline of week 12 in comparison to day 1, 271 
respectively. When compared to control treatment, changes in FMD after aronia 272 
extract and aronia whole fruit consumption were significantly higher by 1.2 % (95 % 273 
CI: 0.36 to 1.97) and 0.9 % (95 % CI: 0.13 to 1.72), respectively (Figure 2, 274 
Supplementary Table 4).        275 
Acute improvements in FMD were also investigated with a significant increase in 276 
FMD of 1.4 ± 0.2 % and 1.5 ± 0.2 % observed after 2 h consumption of aronia 277 
extract on day 1 and week 12 in comparison with baseline, respectively (Figure 2, 278 
Supplementary Table 4). In comparison with control, aronia extract increased 279 
significantly by 1.1 % (95 % CI: 0.37 to 1.78) and 1.7 % (95 % CI: 0.62 to 2.34) after 280 
2 h  on day 1 and week 12, respectively. No significant acute FMD changes with 281 
respect to baseline or control were observed for the aronia whole fruit group (Figure 282 
2, Supplementary Table 4). 283 
No significant differences in the secondary outcomes including peripheral and central 284 
blood pressure, arterial stiffness and blood lipids were observed in any of the 285 
treatment groups (Supplementary Tables 4 and 5). 286 
3.5 Phenolic metabolites increase in plasma after aronia consumption 287 
Detailed targeted metabolomics analysis of plasma samples was performed and 63 288 
phenolic metabolites were quantified at baseline and after consumption of all capsules, 289 
including derivatives of hippuric acids, benzoic acids, hydroxycinnamic acids, 290 
phenylacetic acids, propionic acids, benzaldehydes, catechols, pyrogallols, flavonols 291 
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and valerolactones (Supplementary figure 1). Most metabolites were present in 292 
nanomolar concentrations, except for hippuric acid, benzoic acid, phenylacetic acid 293 
and 3-(4-hydroxyphenyl)propionic acid, which were present at micromolar levels even 294 
at baseline. The highest total (poly)phenol concentrations were found 2 h upon extract 295 
consumption and mounted up to 301 ± 239 µM. The extract group showed increases 296 
in total (poly)phenol concentrations of 166 ± 171 µM and 30 ± 156 µM after 2 h and 297 
12 weeks respectively. The whole fruit group showed substantially lower plasma total 298 
(poly)phenol increases of 43 ± 125 µM and 14 ± 106 µM after 2 h and 12 weeks of 299 
consumption respectively. No significant differences in total plasma (poly)phenols 300 
were found between the three intervention groups at baseline, with the exception of 301 
phenylacetic acid (p=0.01), 2-hydroxybenzoic acid (p<0.001), homovanillic acid 302 
(p=0.048) and homovanillic acid sulfate (p=0.04), which were significantly higher in the 303 
aronia whole fruit group (data not shown).   304 
At 2 h postconsumption, 48 compounds increased significantly with respect to baseline 305 
in the aronia extract group (19 hydroxycinnamic acid derivatives, 13 benzoic acids, 5 306 
flavonols, 4 phenylacetic acids, 2 propionic acids, 2 benzaldehydes, 1 hippuric, 1 307 
pyrogallol and 1 valerolactone), while 22 compounds increased significantly after 308 
consumption of the aronia whole fruit (9 benzoic acids, 4 hydroxycinnamic acids, 3 309 
phenylacetic acids, 2 flavonols, 2 benzaldehydes, 1 hippuric and 1 pyrogallol 310 
derivative).  Only one compound, 1-Methylpyrogallol-O-sulfate, increased significantly 311 
after consumption of the control capsule.   312 
Repetitive intake of the capsules for 12 weeks led to significantly increased baseline 313 
plasma levels of 18 compounds in the aronia extract group, 10 compounds in the 314 
whole berry group and 4 compounds in the control group. The chronic changes 315 
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observed in the treatment groups were predominantly driven by phenylacetic acids, 316 
benzoic acids, hydroxycinnamic acids, flavonols and benzaldehydes (Figure 3). 317 
On week 12, plasma phenolic metabolites also increased significantly 2 h post-318 
consumption of aronia extract (2 hippuric acids, 5 benzoic acids, 7 hydroxycinnamic 319 
acid derivatives, 2 phenylacetic acids, 2 benzaldehydes, 2 flavonols, 1 propionic acid 320 
and 1 valerolactone) and aronia whole fruit (2 hippuric acids, 5 benzoic acids, 6 321 
hydroxycinnamic acid derivatives, 2 benzaldehydes, 1 phenylacetic acid, 1 propionic 322 
acid, 1 catechol derivative and 1 flavonol), while only 1 compound (phenylacetic acid) 323 
increased in the control group.  324 
Correlation analysis between changes in plasma metabolites and changes in flow-325 
mediated dilation with respect to baseline revealed significant correlations in 20 326 
metabolites after aronia extract consumption and in 5 metabolites after consumption 327 
of the whole fruit treatment (Table 3).  328 
3.6 Effects on the gut microbiota correlations with plasma (poly)phenol metabolites 329 
Faecal samples were taken on the first and last day of the study to conduct genomic 330 
analysis of microbial communities. To test the hyphothesis that aronia supplements 331 
can lead the human gut microbiome to different configurations, we first analyzed the 332 
overall microbiome diversity - described in terms of the diversity within a sample, (i.e. 333 
alpha diversity) and between samples (beta diversity). Microbial diversity was very 334 
high and not significant in any of the treatment groups after aronia intake (data not 335 
shown). To explore the relationship between (poly)phenol metabolites and gut 336 
microbial genera, correlation heatmaps were created (Figure 4). The change in a 337 
subset of metabolites measured in circulation after 12-week intake of both extract and 338 
control capsules were correlated with the corresponding changes in gut microbial 339 
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genera abundances (Figure 4A). In a similar way, a correlation heatmap was 340 
performed using data from whole fruit and control groups (Figure 4B). At a first glance, 341 
Figure 4 shows that most of the correlations were not significant in either of the 2 342 
matrices. However, the figure clearly shows that significant correlations were found in 343 
both matrices, with more significant associations after intake of the extract compared 344 
to whole fruit. Furthermore, Random Forests was applied to predict the bacterial 345 
genera that would discriminate between the different treatment groups. Treatment-346 
discriminatory bacterial genera were identified with distinctive modifications in their 347 
relative abundances, which were validated by Wilcoxon signed-rank tests with the 348 
following results: the aronia extract group had a significant higher abundance of 349 
Anaerostipes (+10.6%, p=0.01), the whole fruit group showed significant increases in 350 
Bacteroides (+193 %, p=0.01) and Clostridium XiVb was significantly higher (+2.5 %, 351 
p=0.01) after placebo treatment (Supplementary Figure 3). The difference of the 352 
changes in % abundancy were also calculated between treatment groups and 353 
revealed significant higher increases in Anaerostipes  (21 %, p=0.04) when comparing 354 
aronia extract group to placebo group (Supplementary Figure 4).  355 
356 
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4. Discussion 357 
In the present study, we showed for the first time that daily consumption of aronia 358 
whole fruit powder as well as a polyphenol-rich aronia berry extract over 12 weeks 359 
improved FMD by 0.9 ± 0.4 and 1.2 ± 0.4 %, respectively as compared to control. In 360 
addition, acute (2 h) improvements were observed after intake of aronia extract on day 361 
1 (1.1 %; 95 % CI: 0.37 to 1.78) and after 12 weeks (1.5; 95 % CI: 0.62 to 2.34) with 362 
respect to control. The effects were paralleled with a baseline increase in plasma 363 
phenolic metabolites and with significant changes in the gut microbiota populations. 364 
Safety parameters for capsule intake were measured and based on the results in 365 
Supplementary Table 2, the capsules were considered safe with no associated 366 
adverse events. Intake of the aronia extract and whole fruit capsules significantly 367 
improved the first outcome - FMD - for 1.0 ± 0.2 % (p = 0.0006) and 0.8 ± 0.3 % (p = 368 
0.049) after 12 weeks supplementation. Being a validated prognostic marker for 369 
cardiovascular risk (29), the predictive FMD strength towards CVD risk was previously 370 
analyzed in a meta-analysis of 23 RCTs (13422 participants) where improvement in 1 371 
% FMD was associated with a decrease in overall CVD risk of 8 to 10 % over 4 years 372 
(30). It came to our attention that very few studies reported FMD improvements after 373 
repetitive intake (poly)phenol-rich foods in healthy people (5, 31-34). In one study, by 374 
Khan et al., a blackcurrant juice (204 mg TP) improved baseline FMD significantly by 375 
1.1 % in healthy people after 6 weeks of daily intake (34). The anthocyanin dose given 376 
by Khan et al. (36 mg) was very similar than the one present in the aronia extract 377 
capsules from this study (29 mg) and could explain why improvements in FMD are 378 
comparable with the one found in our study (1.1 % by Khan et al. vs. 1.0 % in current 379 
study), indicating that daily achievable doses of aronia might be effective in improving 380 
and maintaining vascular function over a longer period. The applicability of our findings 381 
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is underlined by an updated publication of EFSA requirements for FMD-based health 382 
claims related to cardiovascular health (35). In January 2018, EFSA stated that a 383 
sustained (at least 4 weeks) increase in FMD after an overnight fast in response to a 384 
food intervention is regarded as a beneficial physiological effect. As compared to the 385 
1.0 % improvements in FMD observed after extract consumption, slightly lower FMD 386 
enhancement (0.68 %, 95% CI 0.46–0.90) were found after statin therapy in a meta-387 
analysis of 46 RCTs (36), which highlights the clinical relevance of repetitive aronia 388 
intake in established primary and secondary prevention applications. Significant acute 389 
improvements in FMD were also found 2 hours upon consumption of the aronia extract 390 
(1.4 ± 0.2 %, p < 0.0001) but not after whole fruit intake (0.4 ± 0.2 %, p = 0.7) 391 
(Supplementary table 4). The low (poly)phenol content in the whole fruit capsules 392 
might not have been enough to elicit acute FMD changes, which was partly reflected 393 
in the plasma of volunteers 2 h post-consumption where extract consumers showed 4 394 
times higher increases in total plasma (poly)phenol concentration than whole fruit 395 
consumers. We cannot discard that there may be other components in the whole fruit, 396 
such as fibers and vitamins, that may be responsible for the sustained effects in 397 
endothelial function observed in this work. Only one other study investigated plasma 398 
phenolic acid concentrations after intake of a 500 mg aronia extract capsule with 399 
increases in 5 plasma and 8 urine (poly)phenols and identified hippuric acid as major 400 
recovered metabolite (37). In our current work, a much more extensive targeted 401 
metabolomics approach using 63 authentic (poly)phenol standards - including 23 402 
phase II sulfate and glucuronide conjugates - was carried out.  The analysis showed 403 
significant increases in aronia-derived plasma (poly)phenols upon intervention. 404 
Various studies demonstrated that anthocyanins are broken down in several key 405 
intermediates, including hippuric acid, protocatechuic acid, and phenylproprionic acids 406 
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(38-41). This is in agreement with our results where hippuric acids, cinnamic acids and 407 
propionic acids were increased after consumption of both aronia treatments 408 
(Supplementary figure 1). Interestingly, 12-week baseline increases in total 409 
(poly)phenols was twice as high for the extract group (30 µM) as compared to the the 410 
whole fruit group (14 µM). Even though whole fruit treatment was low in (poly)phenols, 411 
the 14 µM increase in plasma polyphenols might explain the significant baseline FMD 412 
improvements of 0.8 % 12 weeks after consumption. In addition, twice the amount of 413 
phenylacetic acids were quantified in volunteers ingesting the aronia extract compared 414 
to aronia whole fruit, indicating a difference in absorption depending on the treatment 415 
given (Supplementary Figure 2).  It must be considered that the (poly)phenol content 416 
in aronia whole fruit capsules might have been underestimated due to the presence of 417 
non-extractable (poly)phenols bound to fibers. Actually, it was previously shown that 418 
coarse milling, a milling process that creates 90 nm nanoparticles, could increase the 419 
total (poly)phenol content by 40 to 50 % (42). To further explore the relationship 420 
between aronia berry-derived (poly)phenols and vascular function, a correlation 421 
analysis was performed (Table 4). A total of 24 metabolites correlated significantly 422 
upon intake of aronia with the most abundant ones being hydroxycinnamic acids and 423 
benzoic acids (Table 4). Interestingly, no correlations were found after acute (2 h) or 424 
chronic (12 wks) intake of whole fruit capsules. Assessing the bioactivity of dietary 425 
(poly)phenols in vivo remains a challenge and is still largely unknown. It is believed 426 
that dietary (poly)phenols in the nM range could increase nitric oxide (NO) availability 427 
and therefore improve NO-dependent FMD responses (44, 45). Over half of the 428 
quantified plasma phenolic acids in the current study were previously identified as gut 429 
microbial breakdown products (46, 47) and other than improving vascular health, 430 
phenolic acids are also believed to modulate the gut microbiome (48). Research 431 
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suggests that changes in microbial communities could protect against diet-induced 432 
obesity and cardiometabolic diseases (49). Furthermore, several studies have 433 
attributed prebiotic effects to (poly)phenols as they would improve growth of 434 
Lactobacilli and Bifidobacteria in several in vitro models and clinical studies (50, 51). 435 
To explore whether plasma (poly)phenol metabolites could, in part, be responsible for 436 
the changes in gut microbial abundancies observed, a correlation analysis was 437 
performed (Figure 4). Even though, most of the correlations were not significant, 438 
clearly more significant associations were found after intake of aronia extract 439 
compared to whole fruit. These findings show, that after 12 weeks of intake, volunteers 440 
in the extract group showed more associations with modulated gut microbe genera 441 
compared to the whole fruit group. In addition, our data identified a significant increase 442 
in Anaerostipes abundance after aronia extract consumption (Supplementary figures 443 
3 and 4). It is suggested that the Anaerostipes genus plays an important functional 444 
role in the gut ecosystem due to the ability to produce butyrate from lactate (52). 445 
Butyrate was associated with beneficial effects in various diseases such as genetic 446 
metabolic diseases, hypercholesterolemia, insulin resistance, and ischemic stroke and 447 
colon cancer (53). A notable limitation of this work is that the study population 448 
consisted of a group of healthy young men. Therefore, our findings cannot be directly 449 
extrapolated to all segments of the general population. The study also has notable 450 
strengths: an extensive metabolomics analysis of plasma (poly)phenols in tandem with 451 
the primary outcome made it possible to correlate plasma levels with FMD as well as 452 
with gut microbial genera. In conclusion, our present data indicates that consumption 453 
of dietary achievable amounts of Aronia melanocarpa by healthy individuals can lead 454 
to clinically relevant improvements in endothelial function after an overnight fast. 455 
Furthermore, we linked plasma phenolic metabolites to vascular benefits and 456 
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observed significant changes in gut microbial populations. Our results indicate that 457 
consumption of aronia berry (poly)phenols as part of a balanced and healthy diet may 458 
help to maintain cardiovascular health in young individuals at low risk of CVD.   459 
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Figure Legends 
Figure 1A. Aronia study flow.   
Figure 1B. Study protocol of the randomised controlled study. FMD, flow-mediated 
dilation; PWV, pulse wave velocity; AIX, augmentation index. 
Figure 2A. FMD change from baseline (CFB) 2h post-consumption of the control, 
aronia whole fruit or aronia extract capsules. 
Figure 2B. FMD change from baseline (CFB) three months after daily consumption 
of the control, aronia whole fruit or aronia extract capsules. 
Figure 2C. FMD change from baseline (CFB) at 2h post-consumption and after three 
months daily consumption of the control, aronia whole fruit or aronia extract 
capsules. 
Figure 3. Plasma (poly)phenol metabolites after consumption of aronia berries. 
Figure 3A. Total hippuric acids 
Figure 3B. Total benzoic acids 
Figure 3C. Total cinnamic acids 
Figure 3D. Total phenylacetic acids 
Figure 3E. Total benzaldehydes 
Figure 3F. Total catechols 
Figure 3G. Total pyrogallols 
Figure 3H. Total flavanols 
Figure 3I. Total propionic acids 
Figure 4. Correlation heatmap of plasma metabolites and gut microbiome. A. 
Changes in metabolite concentrations versus changes in abundance of microbial 
genera upon 12-week consumption of aronia extract and control (n = 43). B. Changes 
in metabolite concentrations versus changes in abundance of microbial genera upon 
12-week consumption of aronia whole fruit and control (n = 43). Correlations were 
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performed including controls in two independent analyses: aronia extract + control and 
aronia whole fruit + control. Values are represented as spearman rho, *p < 0.05. 
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Tables 
Table 1.  (Poly)phenol content of intervention capsule 
Per capsule (500 mg) Extract Whole fruit Control 
  Mean SD Mean SD Mean SD 
Flavonols (mg) 35 0.3 2.6 0.1 0 0 
Quercetin (µg) 1625 395 575 430 0 0 
Quercetin-3-glucoside (µg) 8879 970 534 33 0 0 
Quercetin-3-galactoside (µg) 7859 68 816 42 0 0 
Quercetin-3-rhamnoside (µg) 9 1.5 0 0 0 0 
Quercetin-3-rutinoside (µg) 15797 613 610 20 0 0 
Kaempferol (µg) 18 19 27 30 0 0 
Kaempferol-3-glucoside (µg) 229 21 0 0 0 0 
Myricetin (µg) 6.5 7 2.5 2.5 0 0 
Myricetin-3-glucoside (µg) 76 8.5 0 0 0 0 
Isorhamnetin (µg) 71 24 32 18 0 0 
Hesperetin (µg) 1.5 1.5 1 1.5 0 0 
Naringenin (µg) 5.5 1 2 0.5 0 0 
Hydroxycinnamic acids (mg) 33 0.4 1.7 0 0 0 
Vanillic acid  (µg) 0.5 0.5 0 0 0 0 
p-coumaric (µg) 119 17 3.5 4 0 0 
m-coumaric (µg) 28 12 1.5 1.5 0 0 
o-coumaric (µg) 11 4 0.5 0.5 0 0 
Caffeic acid (µg) 819 22 125 1.5 0 0 
Dihydrocaffeic acid (µg) 25 11 2.5 6.5 0 0 
Ferulic acid (µg) 84 35 6.5 4 0 0 
Isoferulic acid (µg) 225 150 17 19 0 0 
Neochlorogenic acid (µg) 8360 374 425 49 0 0 
Chlorogenic acid (µg) 21341 1180 1116 50 0 0 
Cryptochlorogenic (µg) 1746 17 30 2 0 0 
Benzoic acids (mg) 2.8 0 0.5 0 0 0 
Benzoic acid (µg) 295 23 16 17 0 0 
Gallic acid (µg) 61 15 1 0.5 0 0 
4-hydroxybenzoic acid (µg) 59 1.5 23 3 0 0 
3-hydroxybenzoic acid (µg) 6.5 7 0.5 0.5 0 0 
2-Hydroxybenzoic acid (µg) 25 28 5 5.5 0 0 
Protocatechuic acid (µg) 2396 105 450 18 0 0 
Phloretin (µg) 0.5 0.5 0 0 0 0 
Epicatechin (µg) 101 5.5 0 0 0 0 
Total phenolics (mg) 70 1.5 4.8 0.6 0 0 
Anthocyanins (mg) 29 - 3.6 - 0 0 
Proanthocyanidins (mg) 16 3.2 3.3 0.9 0 0 
Total (poly)phenols (mg) 115 4.7 12 1.4 0 0 
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Table 2. Baseline characteristics of the population included in the study. 
Population characteristics All Control Whole fruit Extract 
  Mean ± SD 
Age (years) 24 ± 5.3 23 ± 4.4 24 ± 5.2 24 ± 6.3 
Height (cm) 177 ± 7.2 176 ± 8.5 176 ± 5.9 178 ± 7.3 
Weight (Kg) 71 ± 8.3 69 ± 6.8 70 ± 9.8 74 ± 7.5 
BMI (kg/m2) 23 ± 2.1 22 ± 1.6 23 ± 2.6 23 ± 1.9 
PSBP (mmHg) 119 ± 10.6 118 ± 11 119 ± 8.4 119 ± 12.6 
PDBP (mmHg) 68 ± 7.9  68 ± 6.2 69 ± 9.1 67 ± 8.2 
CSBP (mmHg) 101 ± 7.9 100 ± 7 102 ± 8.3 101 ± 8.6 
CDBP (mmHg) 70 ± 9.2 70 ± 7.4 71 ± 10.1 69 ± 9.8 
HR (bpm) 62 ± 9.8 62 ± 8.9 63 ± 9.4 62 ± 11.4 
PWV (m/s) 5.5 ± 1.1 5.1 ± 1 5.7 ± 1.2 5.6 ± 1.2 
AIx (%) -3.6 ± 10  -3.8 ± 10.7 -2.6 ± 9.4 -4.4 ± 10.3 
Body fat (%) 15 ± 4.0 15 ± 3.4 14 ± 4.4 15 ± 3.9 
BMR (Kcal) 1787 ± 188 1736 ± 191 1770 ± 192 1848 ± 171 
PGLU (mmol/L) 5 ± 0.3 4.9 ± 0.3 5.0 ± 0.4 5 ± 0.3 
PLT (109/L) 225 ± 38.8 228 ± 31.9 221 ± 38 225 ± 46.1 
Urea (mmol/L) 5.8 ± 1.3 5.9 ± 1.5 5.5 ± 0.8 6.0 ± 1.5 
Creatin (mmol/L) 80 ± 10.2 77 ± 9 77 ± 7.7 84 ± 12.2 
ALP (IU/L) 66 ± 16.3 70 ± 18.4 63 ± 16.4 65 ± 14.3 
AST (IU/L) 26 ± 12.6 23 ± 6.7 24 ± 7.7 30 ± 18.5 
GGT (IU/L) 17 ± 14.4 17 ± 9.5 16 ± 11.3 19 ± 20.2 
CHOL (mmol/L) 4.1 ± 0.7 4.1 ± 0.8 4 ± 0.6 4.3 ± 0.7 
TRIG (mmol/L) 0.8 ± 0.4 0.8 ± 0.3 0.7 ± 0.3 1.0 ± 0.5 
HDL (mmol/L) 0.4 ± 0.3 1.3 ± 0.2 1.5 ± 0.3 1.3 ± 0.2 
LDL (mmol/L) 2.4 ± 0.6 2.4 ± 0.8 2.2 ± 0.5 2.5 ± 0.6 
LDH (IU/L) 150 ± 22.9 147 ± 22.6 147 ± 27.6 156 ± 17 
Smoking (%) 14 20 13 9 
          
689 
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Table 3. Plasma (poly)phenols correlation with FMD. 
 FMD vs  plasma 
(poly)phenols 
Aronia extract 
(2 h) 
Aronia extract 
(12 wks) 
Aronia extract 
(12 wks, 2 h) 
Aronia whole fruit 
(12 wks, 2 h) 
 Spearman ρ 
Total (poly)phenols 0.34    
2-Hydroxyhippuric acid 0.36    
Protocatechuic acid   0.41  
2-Hydroxybenzoic acid   0.30  
3-Hydroxybenzoic acid  0.30 0.41 0.38 
4-Hydroxybenzoic acid 0.35    
Vanillic acid-4'-O-sulphate 0.33    
Isovanillic acid  0.31   
Gallic acid   0.45  
Dihydroferulic acid 0.58    
Dihydro isoferulic acid 0.41    
p-Coumaric acid   0.30  
o-Coumaric acid    0.36 
Ferulic acid-4'-O-sulphate    0.32 
Isoferulic acid-3'-O-β-D-
glucuronide 
0.39    
Dihydroferulic acid-4'-O-β-D-
glucuronide 
0.32    
Dihydro isoferulic acid-3'-O-β-
D-glucuronide 
0.37    
Dihydro isoferulic acid-3'-O-
sulphate 
 0.35   
Phenylacetic acid 0.48  0.44 0.33 
3,4-Dihydroxyphenylacetic acid    0.31 
4-Hydroxybenzaldehyde   0.39  
Catechol-O-sulphate 0.44    
Kaempferol   0.42  
Quercetin-3'-O-β-D-
glucuronide 
0.40    
(4R)-5-(3'-Hydroxyphenyl)-γ-
valerolactone-4'-O-sulfate 
0.39    
Correlations between changes in plasma metabolite concentrations (with respect to baseline) and FMD 
changes (with respect to baseline). Correlations were performed by correlating control and aronia extract 
outcomes in one analysis and perform a second control and aronia whole fruit correlation in an 
independent analysis. This was repeated for data obtained from acute (2 h), chronic (12 wks) and acute 
on chronic (12 wks, 2 h). No correlations were found between aronia whole fruit and FMD on the acute 
and chronic level. Spearman was used for correlations of non-parametric data. All data represented had 
p < 0.05.  
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Supplementary material 
Supplementary Figure 1. Plasma (poly)phenol concentrations. Figure 3A, 3B, 3C 
and 3D display the plasma concentration of 63 quantified (poly)phenols. 
Supplementary Figure 2. The pie charts display the ratio of abundance (%) of 
(poly)phenol groups with respect to total (poly)phenols in plasma after substraction 
of baseline 12-weeks from the baseline values on day 1 in extract and whole fruit 
consumers. 
Supplementary Figure 3. Changes in the gut microbiome associated to aronia 
treatments. Top 10 features from aronia extract (A), aronia whole fruit and control (C) 
data sets, as revealed by Random Forests. Red dots denote bacterial genera 
significantly discriminant of the final microbiome structure respect to the initial 
configuration for each treatment. Differences in the relative abundances of each 
relevant genera were investigated using Wilcoxon signed-rank tests and visualized 
by both dot plots and box plots. Paired samples from the same individual were 
connected by a black line. 
Supplementary Figure 4. Significant increases in Anaerostipes abundancy upon 
intake of the aronia extract compared to control. Significance was tested using a 
paired t-test of the changes in microbial abundanties. 
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Supplementary Table 1. Nutrient content of the three intervention capsules. 
Aronia whole fruit Aronia extract Control
Total fat (mg) 30 20 0.1
Protein (mg) 30 0.1 0.1
Total carbohydrates (mg) 480 530 550
Calories (cal) 2300 2300 2200
Dietary fibres, Total (mg) 260 120 20
Insoluble (mg) 30 0.1 0.1
Soluble (mg) 240 120 10
Vitamin C (mg) 70 0.1 20
Supplementary Table 2 -  Safety
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2
-0.005263 0.836 -0.06917 0.9163 -0.03828
(-1.14; 1.13) (-0.22; 1.89) (-1.13; 0.99) (-0.28; 2.11) (-1.23; 1.16)
-0.04816 -0.08696 -0.7879 0.00778 -0.6144
(-1.15; 1.06) (-1.11; 0.93) (-1.82; 0.24) (-1.01; 1.03) (-1.64; 0.41)
-1.068 -2.702 -1.421 -1.517 -0.3349
(-4.39; 2.26) (-5.80; 0.39) (-4.52; 1.68) (-4.86; 1.83) (-3.68; 3.01)
-0.5421 -1.951 -0.05336 -1.414 0.4952
(-2.18; 1.09) (-3.47; -0.43)** (-1.57; 1.47) (-3.06; 0.23) (-1.15; 2.14)
-1.408 -2.682 0.5593 -1.38 1.711
(-5.66; 2.85) (-6.64; 1.28) (-3.40; 4.52) (-5.13; 2.37) (-2.04; 5.46)
2.237 -6.291 -1.935 -6.904 -3.041
(-10.86; 15.33) (-18.48; 5.90) (-14.12; 10.25) (-14.06; 0.26) (-10.2; 4.12)
-1.504 -0.887 -0.5318 0.5867 0.6451
(-5.09; 2.08) (-4.18; 2.41) (-3.90; 2.84) (-0.70; 1.88) (-0.67; 1.96)
3.271 5.478 1.409 2.32 -2.301
(-5.79; 12.33) (-2.86; 13.82) (-7.12; 9.94) (-6.82; 11.46) (-11.64; 7.04)
0.4224 0.2043 0.1636 -0.1957 -0.2619
(-0.31; 1.15) (-0.47; 0.88) (-0.52; 0.85) (-0.62; 0.23) (-0.70; 0.17)
0.3387 0.01304 0.1773 -0.3343 -0.1426
(-0.08; 0.76) (-0.37; 0.40) (-0.22; 0.57) (-0.64; 0.03) (-0.45; 0.17)
Values are presented as mean ± SD
9.1 ± 0.8 8.9 ± 0.9 9 ± 1 0.03* 0.04* 0.3
13 ± 0.4 13.2 ± 0.4 0.004* 0.9 0.113.2 ± 0.7
Mean platelet volume (fL) 11.0-15.0 8.6 ± 0.8 9 ± 1.3 8.9 ± 0.8
Red cell distribution width 
(%)
7.4-10.4 13 ± 0.5 13.4 ± 0.5 13.2 ± 0.6
332 ± 9.3 327.9 ± 9.4 329.3 ± 10.8 0.5 0.004* 0.7
92.7 ± 3.7 92.2 ± 3 0.02* 0.0006* 0.04*91.1 ± 5.5
Mean corpuscular 
hemoglobin concentration 
(g/dL)
320-370 329.2 ± 18.2 332.4 ± 8.4 326.5 ± 11.6
Mean corpuscular volume 
(fL)
77-95 91.3 ± 3.8 89.8 ± 5.4 92 ± 5.5
56.3 ± 16.4 65.4 ± 14.3 63.5 ± 14.3 0.6 0.003* 0.5
11.3 ± 3.9 11.9 ± 4.9 0.4 0.007* 0.712.3 ± 6.7
Alkaline phosphatase (IU/L) 30-130 69.5 ± 18.4 71.7 ± 21.3 62.6 ± 16.4
Total bilirubin (umol/L) 3-20 13.3 ± 5.8 11.8 ± 3.9 15 ± 6.7
43.1 ± 1.6 43.8 ± 1.7 43.8 ± 2.7 0.2 0.0003* 0.8
70.7 ± 3.5 69.3 ± 6.8 0.2 0.004* 0.268.9 ± 3.1
Albumin (g/L) 35-50 43.7 ± 2.2 43.2 ± 1.6 45.1 ± 2.5
Total protein (g/L) 60-80 69.7 ± 4.2 68.6 ± 3.6 71.6 ± 3.3
5.4 ± 1.6 6 ± 1.5 5.2 ± 1.4 0.9 0.8 0.01*
141.5 ± 1.6 141.4 ± 1.7 0.9 0.003* 0.8141.6 ± 1.1
Urea (mmol/L) 3.4-7 5.9 ± 1.5 5.8 ± 1.7 5.5 ± 0.8
Na (mmol/L) 135-145 140.9 ± 1.7 140.9 ± 1.5 140.8 ± 1.1
Δfull spectrum P-value Δextract P-value
Difference
(Δwhole fruit - 
Δcontrol)
Difference
(Δextract - 
Δcontrol)
Normal range
Control Whole fruit Extract
Δcontrol P-value
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2
Energy (kcal) 2182 ± 422 2136 ± 569 2206 ± 459 2110 ± 482 2049 ± 579 1970 ± 463
Protein (g) 100 ± 24 100 ± 35 98 ± 32 101 ± 30 110 ± 32 106 ± 35
Carbohydrates (g) 232 ± 64 229 ± 65 232 ± 40 209 ± 45 216 ± 66 198 ± 51
Fibres (g) 83 ± 16 82 ± 28 88 ± 26 85 ± 29 78 ± 26 76 ± 24
Fat (g) 19 ± 5 21 ± 5 20 ± 5 20 ± 6 19 ± 5 19 ± 6
Vitamin A (mg) 5 ± 3 5 ± 3 5 ± 2 5 ± 3 6 ± 4 6 ± 5
Thiamin (mg) 13 ± 3 14 ± 5 12 ± 3 13 ± 4 13 ± 4 13 ± 4
Riboflavin (mg) 12 ± 4 13 ± 5 13 ± 6 13 ± 5 13 ± 3 12 ± 3
Niacin (mg) 347 ± 107 339 ± 113 334 ± 112 338 ± 90 360 ± 110 353 ± 108
Vitamin B6 (mg) 16 ± 5 16 ± 5 16 ± 5 16 ± 4 16 ± 5 15 ± 4
Folates (μg) 1729 ± 597 1842 ± 561 1597 ± 553 1772 ± 562 1592 ± 482 1693 ± 554
Vitamin B12 (μg) 37 ± 12 38 ± 22 37 ± 20 41 ± 24 41 ± 17 45 ± 24
Vitamin C (mg) 612 ± 543 743 ± 425 554 ± 362 672 ± 490 542 ± 362 577 ± 383
Vitamin D (μg) 20 ± 11 18 ± 14 24 ± 16 28 ± 22 27 ± 14 27 ± 13
Vitamin E (mg) 69 ± 22 76 ± 30 77 ± 24 74 ± 37 67 ± 31 70 ± 25
Sodium (g) 21 ± 7 19 ± 6 19 ± 5 19 ± 5 17 ± 6 17 ± 6
Potassium (g) 22 ± 47 22 ± 57 21 ± 6 22 ± 7 22 ± 5 21 ± 6
Calcium (g) 6 ± 2 6 ± 2 6 ± 2 6 ± 2 6 ± 2 6 ± 2
Magnesium (g) 2202 ± 499 2237 ± 547 2187 ± 758 2234 ± 671 2088 ± 479 2054 ± 599
Phosphorus (g) 10 ± 2 10 ± 3 10 ± 4 11 ± 3 11 ± 3 10 ± 3
Iron (mg) 91 ± 26 98 ± 26 95 ± 45 90 ± 21 86 ± 23 84 ± 23
Copper (mg) 9.4 ± 3 23 ± 54 10* ± 4 24* ± 52 8.7 ± 3 8.7 ± 3
Zinc (mg) 7* ± 18 8* ± 40 72 ± 25 79 ± 31 75 ± 26 74 ± 30
Chloride (g) 28 ± 9 25 ± 8 27 ± 7 27 ± 7 25 ± 8 24 ± 8
Selenium (μg) 408 ± 120 399 ± 211 445 ± 192 426 ± 208 467 ± 188 468 ± 171
Fluoride (mg) 7 ± 6 8.1 ± 5 7.4 ± 4 6.6 ± 5 6.5 ± 4 6.9 ± 4
Iodine (μg) 831 ± 310 839 ± 516 902 ± 685 923 ± 602 947 ± 361 962 ± 397
Total polyphenols (mg) 419 ± 52 553 ± 86 568 ± 92 584 ± 84 606 ± 76 465 ± 73
Anthocyanins (mg) 11 ± 4 19 ± 7 20 ± 5.5 24 ± 7.3 34 ± 8.7 31 ± 9.3
Flavan-3-ols (mg) 71 ± 17 139 ± 44 153 ± 40 163 ± 37 130* ± 20 74* ± 13
Proanthocyanidins (mg) 46 ± 12 56 ± 11 52 ± 10 70 ± 13 78 ± 16 87 ± 24
Flavonols (mg) 37 ± 4.2 39 ± 1 45 ± 9 44 ± 0.7 42 ± 6.1 36 ± 0.7
Flavones (mg) 3.8 ± 0.8 5 ± 42 3.2 ± 0.7 3.4 ± 34 3 ± 0.6 3.6 ± 35
Phenolic acids (mg) 157 ± 36 192 ± 5 180 ± 36 156 ± 5.2 209 ± 45 149 ± 6.7
Stilbenes (mg) 0.1 ± 0.05 0.2 ± 0 0.2 ± 0.1 0.3 ± 0.2 0.1 ± 0.02 0.1 ± 0.03
Other
1
 (mg) 93 ± 5.9 103 ± 4 115 ± 11 123 ± 14 102 ± 6.2 84 ± 8.7
Supplementary Table 3. Average macro-, micronutrient and (poly)phenol intakes taken from 7-day 
diet diaries at baseline and during the 12-week intervention. Values are represented as mean ± SEM
1
Others: Chalcones, Dihydrochalcones, Isoflavonoids, Lignans, Hydrobenzoic acids, Hydroxycinnamic acids, 
Hydroxyphenylacetic acids, Hydroxphenylpropanoic acids, Resveratrol, Other. 
Control Aronia whole fruit Aronia extract
*significant difference (Δvisit 2-visit 1) at p<0.05
Supplementary  Table 3. Effects of Aronia berry after 12-week consumption on vascular parameters, blood pressure and heart rate
Mean value 95% CI Mean value 95% CI Mean value 95% CI Mean value 95% CI Mean value 95% CI Mean value 95% CI
4.153 -3.40; 11.71 -0.2273 -4.98; 4.52
FMD, flow mediated dilation; PWV, pulse wave velocity; AIx, augmentation index; PSBP, peripheral systolic blood pressure; PDBP, peripheral diastolic blood pressure; CDBP, central systolic blood pressure; CDBP, central diastolic blood pressure
# Differences are calculated from an unpaired t test comparing ARONIA WHOLE FRUIT and ARONIA EXTRACT with CONTROL changes from baseline
* p<0.05, ** p<0.01, *** p<0.001. Values are represented as mean ± SD
0.5286 -6.95; 8.01 -2.391 -7.09; 2.31 4.935 -1.69; 11.5663 ± 9 55 ± 9 64 ± 11 56 ± 9 2.309 -4.25; 8.87Heart rate (bpm) 62 ± 9 55 ± 7 62 ± 9 56 ± 7 62 ± 11 57 ± 11
-5.82; 8.31 -0.880471 ± 7 4.668 -3.04; 12.37 -2.407 -9.4; 4.59 0.471468 ± 9 72 ± 7 -5.03; 10.53 1.249
66 ± 12 60 ± 12
-6.69; 4.54 2.222 -3.23; 7.67
CDBP (mmHg) 70 ± 7 70 ± 6 72 ± 7 72 ± 7 69 ± 10
-1.776 -7.33; 3.78 2.719 -2.68; 8.11 5.94 -4.01; 15.89102 ± 8 99 ± 9 102 ± 9 101 ± 8
-5.87; 4.11-4.47; 5.41 2.751
-1.815 -7.33; 3.70 0.3627
70 ± 7 71 ± 10 72 ± 10 71 ± 8
-1.074
71 ± 7
-0.4019 -6.65; 5.84 2.813
4.634 -5.22; 14.48
-4.72; 4.64
CSBP (mmHg) 100 ± 7 99 ± 8 103 ± 7 99 ± 7 101 ± 9 100 ± 10 102 ± 8 100 ± 7
-4.27; 5.00 -0.5431 -5.19; 4.10 0.7931 -4.78; 6.37 -0.0394771 ± 7 -1.033
-2.35; 7.98
PDBP (mmHg) 68 ± 6 69 ± 8 71 ± 7 71 ± 7 67 ± 8
-0.5995 -6.78; 5.58 1.132
67 ± 9 70 ± 6 69 ± 7 68 ± 6 69 ± 8
PSBP (mmHg) 118 ± 11 116 ± 10 119 ± 9 119 ± 14 119 ± 13 119 ± 12 118 ± 10 119 ± 10
-5.63; 3.56
-3.98; 6.24 3.522 -2.78; 9.82119 ± 8 116 ± 7 119 ± 9 118 ± 9 0.6579 -5.58; 6.90
-8.34; 7.59 -2.266-6 ± 12 0.913 -7.17; 9.00 1.405 -6.48; 9.29 -2.034-13 ± 12 -3 ± 8
-0.57; 0.77 -0.2847 -0.96; 0.39
AIx (%) -4 ± 11 -11 ± 14 -2 ± 11 -6 ± 9 -4 ± 10
-0.1609 -0.83; 0.51 -0.2645 -0.93; 0.40 0.01914 -0.66; 0.706 ± 1 5 ± 1 6 ± 1 6 ± 1
-7.38; 2.85-7.10; 3.03 -2.545 -10.71; 5.62 -0.3756
-6.771 -24.95; 11.4 5.624
-9 ± 10 -3 ± 9 -9 ± 11 0 ± 10
0.1
129 ± 20
1.167 0.36; 1.97** 1.482
-0.5437 -1.22; 0.13
-4.58; 17.34
PWV (m/s) 5 ± 1 5 ± 1 6 ± 1 6 ± 1 6 ± 1 6 ± 1 6 ± 1 6 ± 1
-5.22; 16.47 0.578 -16.01; 17.16 -3.862 -22.22; 14.5 6.381110 ± 22 -5.266
0.62; 2.34***
Blood flow 
velocity (cm/sec)
120 ± 29 106 ± 25 131 ± 27 107 ± 18 123 ± 24
0.9273 0.13; 1.72* 0.6233
111 ± 22 131 ± 23 113 ± 19 124 ± 22 106 ± 21
FMD (%) 6.4 ± 1.5 6.7 ± 1.7 6.2 ± 1.2 6.0 ± 1.4 6.1 ± 1.0 6.7 ± 1.4 7.3 ± 1.8 7.8 ± 1.8
-21.68; 11.15
-0.23; 1.47 1.075 0.37; 1.78**5.9 ± 1.3 7.4 ± 1.6 6.9 ± 1.7 8.5 ± 1.9 0.07598 -0.62; 0.77
Control Aronia whole fruit Aronia extract Difference (Δ Aronia whole fruit - Δ Control) Difference (Δ Aronia extract - Δ Control)
Baseline 2 h 12 wks 12 wks, 2 h Baseline
12 wks, 2 h
12 wks, 2 h
2 h 12 weeks 12 weeks, 2 h 2 h 12 wks
2 h 12 wks 12 wks, 2 h Baseline 2 h 12 wks
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2
Supplementary  Table 4 Effects  of Aronia berries after 12-week consumption on blood lipids, fasting glucose 
and body composition
BMR, basal metabolic rate.
BMR (Kcal) 1736 ± 191 1752 ± 195 1770 ± 192 1766 ± 180 1848 ± 171 1855 ± 180 -19.25 -50.26; 12.05 -11.89 -43.52; 19.73
15.4 ± 3.9 14.7 ± 3.3 -0.4828 -2.05; 1.08 -0.7036 -2.28; 0.88
73.8 ± 7.7 -1.215 -2.65; 0.22 -0.9005 -2.35; 0.55
Body fat (%) 15.4 ± 3.4 15.8 ± 4 14.2 ± 4.4 14.1 ± 3.7
Body weight (Kg) 69.1 ± 6.8 70.1 ± 7 70.1 ± 9.8 69.8 ± 9 73.9 ± 7.5
5.0 ± 0.3 5.2 ± 0.4 -0.1318 -0.81; 0.55 0.1057 -0.58; 0.79
0.9 ± 0.4 0.01533 -0.25; 0.28 -0.07775 -0.35; 0.19
Fasting glucose 
(mmol/L)
4.9 ± 0.3 5.0 ± 0.3 5.0 ± 0.4 5.2 ± 0.4
Triglycerides 
(mmol/L)
0.8 ± 0.3 0.8 ± 0.3 0.7 ± 0.3 0.8 ± 0.5 1.0 ± 0.5
2.5 ± 0.6 2.6 ± 0.7 -0.1618 -0.50; 0.18 -0.0689 -0.41; 0.27
1.3 ± 0.2 -0.0754 -0.20; 0.05 -0.04833 -0.17; 0.08
LDL-cholesterol 
(mmol/L)
2.4 ± 0.8 2.6 ± 0.8 2.2 ± 0.5 2.1 ± 0.5
HDL-cholesterol 
(mmol/L)
1.3 ± 0.2 1.3 ± 0.3 1.5 ± 0.3 1.4 ± 0.3 1.3 ± 0.2
4.3 ± 0.7 4.2 ± 0.9 -0.2771 -0.69; 0.14 -0.1593 -0.58; 0.26
Control Aronia whole fruit Aronia extract Difference
 (Δ Aronia whole fruit - Δ 
Control)
Difference 
(Δ Aronia extract - Δ 
Control)
Total cholesterol 
(mmol/L)
4.1 ± 0.8 4.3 ± 0.9 4.0 ± 0.6 3.9 ± 0.5
